• Test Code:
    1158 (now 1240)1240
  • Department:
  • Test Synonyms:
    ARVCVentricular ArrhythmiaDSC2DSG2DSPJUPLMNAMYBPC3MYH7PKP2RYR2TGFB3TMEM43TTNFull Gene(s) Analysis
  • CPT Code(s):
    Contact KDL for billing information
Background:

The inherited cardiomyopathies comprise a group of genetically heterogeneous diseases, the most common of which are hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and left ventricular non-compaction (LVNC).  These disorders have an impact across all age groups.  Overall, the prevalence of these disorders is estimated at approximately 1/500 (0.2%). 

ARVC is a type of cardiomyopathy defined by the progressive replacement of the myocardium with fibrous/fatty tissue, which increases the risk of ventricular arrhythmia and sudden death. The prevalence of ARVC is estimated to be between 1/1,000 and 1/1,250. This next-generation sequencing test is designed to detect mutations in the coding region of 12 genes associated with Arrhythmogenic Right Ventricular Cardiomyopathy.

Reasons for Referral:

  • Echocardiogram results suspicious for cardiomyopathy.
  • Clinical presentation consistent with Arrhythmogenic Right Ventricular Cardiomyopathy.
  • Positive family history for Arrhythmogenic Right Ventricular Cardiomyopathy (targeted testing is available if familial mutation is known).
  • Carrier testing.
For detailed information and ordering instructions, please refer to Full Gene Analysis (1240). Genes may be added or removed from the list below if clinically indicated.

The 12 Arrhythmogenic Right Ventricular Cardiomyopathy-associated genes are listed below:

DSC2, DSG2, DSP, JUP, LMNA, MYBPC3, MYH7, PKP2, RYR2, TGFB3, TMEM43, TTN

Methodology:

Specimen Requirements:

Test Performed (Days):

Turn Around Time:

Shipment Sensitivity Requirements:

References:

  1. GeneReviews: McNally et al., 2014, http://www.ncbi.nlm.nih.gov/books/NBK1131/
  2. Genetics Home Reference: http://ghr.nlm.nih.gov/condition/arrhythmogenic-right-ventricular-cardiomyopathy

Additional Info:

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More